Arkolith/Insider Trading/KROS/Form 4

Gordon Carl L

DirectorKeros Therapeutics, Inc. (KROS) · full profile →Form 4 · filed Aug 15, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$11.0M
Net Open-Market Flow
-$11.0M
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 13, 2024Sell(S)221K$44.01$9.7M899K
Aug 13, 2024Sell(S)29K$44.01$1.3M120K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000947871-24-000703) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML